The Diagnostic Bell Tolls for Serum Creatinine in Critical Care
A new commentary in Critical Care critically examines the utility of serum creatinine as a biomarker for acute kidney injury (AKI) in intensive care settings. The article, titled “Ask not for whom the bell tolls: a meditation on the utility of serum creatinine,” prompts a vital discussion on drug toxicity monitoring and therapeutic drug monitoring for agents with renal excretion. It highlights the limitations of relying on a single, delayed pharmacokinetic marker for assessing drug-induced nephrotoxicity and patient organ function, which is central to pharmacodynamics and dose-response considerations in critically ill populations.
Study Significance: For pharmacologists and clinicians, this analysis underscores the need for more sensitive and timely biomarkers to guide drug dosing and prevent adverse drug reactions in vulnerable patients. It directly impacts the field of pharmacokinetics and pharmacodynamics by challenging a cornerstone of therapeutic drug monitoring, urging a shift towards personalized medicine approaches in critical care therapeutics. This reevaluation is crucial for optimizing drug efficacy and safety, particularly for antibiotics, analgesics, and other agents with narrow therapeutic windows.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
